QIAGEN : enhances bioinformatics portfolio with acquisition of OmicSoft

Powerful multi-omics data management solution and highly curated 'omics' data sets complement QIAGEN's industry-leading interpretation solutions

Hilden, Germany, and Germantown, Maryland, January 9, 2017 -QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of OmicSoft Corporation, providing access to OmicSoft's powerful multi-omics data management infrastructure solution as well as expertly curated 'omics' data sets that complement QIAGEN's bioinformatics portfolio that are relied upon by customers worldwide to gain valuable insights into complex biological data.

OmicSoft is recognized for its suite of cutting-edge software solutions that enable scientists and researchers to efficiently analyze and visualize their own data sets and compare them to massive volumes of publicly available 'omics' data sets - such as The Cancer Genome Atlas (TCGA) operated by the U.S. National Cancer Institute - and share results with colleagues. These solutions, which integrate enterprise access and cloud-based resources, are essential in addressing the rapidly growing need of researchers in discovery and translational research to manage, compare and share the massive volumes of data on DNA, RNA and other biological variables generated with next-generation sequencing (NGS) technologies.

OmicSoft is expected to greatly enhance QIAGEN's industry-leading bioinformatics portfolio by adding key features for the management, analysis and sharing of both primary data and analyzed results, while also expanding the range of QIAGEN's translational and clinical applications.

Through the addition of OmicSoft, QIAGEN will now offer solutions across the full spectrum of data management and interpretation needs. Within these infrastructure solutions, OmicSoft adds the ability to mine curated 'omics' data for unpublished findings. QIAGEN will be able to offer:

1. Literature-based interpretation: QIAGEN is the leader in intuitive web-based applications to analyze and interpret the biological meaning of genomic data using rich content from millions of curated articles from scientific and medical literature. The foundation is the Ingenuity Knowledge Base and interpretation tools such as IPA and QIAGEN Clinical Insight (QCI).
2. Intra-institution and inter-institution data management, analysis, sharing and interpretation solutions for data created or owned by a customer as well as for OmicSoft's curated data sets.

In addition, OmicSoft brings to QIAGEN scalable and flexible software architecture solutions that will enable efficient future expansion of QIAGEN's bioinformatics offerings.

'The addition of OmicSoft to QIAGEN's portfolio of Sample to Insight solutions reinforces our position as the gold standard for analysis and interpretation of complex biological data across many different disciplines,' said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.

'The OmicSoft team has deep expertise that will enable QIAGEN to better support customers in managing vast data sets and gaining actionable insights for discovery and translational research,' said Dr. Laura Furmanski, Senior Vice President and Head of the Bioinformatics Business Area at QIAGEN. 'The market opportunity is significant given the expanding use of multiple 'omics' data in research and clinical healthcare. We intend to integrate the OmicSoft solutions into our full bioinformatics interpretation portfolio, and make it a key differentiator in our Sample to Insight offerings.'

OmicSoft offers a portfolio of solutions that collects, curates and standardizes massive amounts of public research data to enable customers to access findings through a single multi-omics platform. Three major solutions combine content with software in the user-friendly Array Suite:

• Land technology - collecting and managing large public data sets in curated knowledge bases in fields such as cancer genomics (OncoLand), cardiovascular, metabolic and immunology (DiseaseLand), and genetic research (GeneticsLand).
• Array Server software - providing the enterprise back-end solution for project management, sample management, data storage and access to the Land databases.
• Array Studio software - providing a graphical user interface to browse, analyze and visualize data from NGS sequencing, microarray and other technologies.

OmicSoft will operate as a QIAGEN company from its headquarters in the Research Triangle region. Dr. Jack Liu, Co-Founder and President, will remain with QIAGEN to lead future product development of the OmicSoft portfolio.

Financial information

Financial terms of the acquisition, which was completed in January 2017 using cash reserves, were not disclosed. On a full-year basis in 2017, QIAGEN expects this acquisition to provide approximately half a percentage point of incremental sales growth, and to be neutral to adjusted earnings per share (EPS).

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2016, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found athttp://www.qiagen.com.

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and integration of acquired technologies and businesses. For further information, please refer to the reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).